title: Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study.
abstract: OBJECTIVE
  In vitro, methotrexate (MTX) is the best modulator for bolus 5-fluorouracil (5FU), whereas folinic acid (FA) is the best for continuous infusion. We evaluated the effect of 5FU modulated by both MTX (bolus administration) and FA (continuous infusion) as second-line treatment of patients with metastatic colorectal cancer.
  
  
  METHODS
  Entry criteria were: at least one 5FU-based chemotherapy regimen as first-line treatment for metastatic disease, or progression within twelve months after 5FU-containing adjuvant therapy. Treatment schedule: MTX 200 mg/m2 i.v. days 1 and 15; 5FU 600 mg/m2 i.v. bolus, days 2 and 16; 5FU 200 mg/m2 i.v. continuous infusion for 21 days, starting on day 29; FA 20 mg/m2 i.v. bolus weekly during the three weeks of 5FU infusion. Cycles were repeated every 56 days. The primary end-point was tumour control rate, including partial responses and stabilizations.
  
  
  RESULTS
  34/35 patients enrolled were evaluable for response. Five (14.7%) had a partial response, 13 (38.2%) disease stabilization, and 16 (47.1%) progressed; tumour control rate was 52.9%. Median TTP was 5.8 months (95% CI 4.03-7.83); 29 patients had died. Median OAS was 15.9 months (95% CI 8.8-21.9). Toxicity was mild.
  
  
  CONCLUSIONS
  The regimen constituted by 5FU modulated by MTX (bolus administration) and FA (continuous infusion) is active as second-line treatment of metastatic colorectal cancer.
authors.affiliation: Division of Medical Oncology, Department of Molecular and Clinical Endocrinology and Oncology, University of Naples Federico II, Naples, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Carlomagno
authors.forename: R
authors.initials: R
authors.lastname: Lauria
authors.forename: M
authors.initials: M
authors.lastname: De Laurentiis
authors.forename: G
authors.initials: G
authors.lastname: Arpino
authors.forename: E
authors.initials: E
authors.lastname: Massarelli
authors.forename: C
authors.initials: C
authors.lastname: Ferrara
authors.forename: A
authors.initials: A
authors.lastname: Milano
authors.forename: A
authors.initials: A
authors.lastname: Vernaglia Lombardi
authors.forename: R
authors.initials: R
authors.lastname: Costanzo
authors.forename: G
authors.initials: G
authors.lastname: Catalano
authors.forename: A R
authors.initials: AR
authors.lastname: Bianco
authors.forename: S
authors.initials: S
authors.lastname: De Placido
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003967:Diarrhea / Q000139:chemically induced; D018450:Disease Progression; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D002955:Leucovorin / Q000627:therapeutic use*; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009367:Neoplasm Staging; D015996:Survival Rate; D016896:Treatment Outcome; D014839:Vomiting / Q000139:chemically induced
chemical_list: D002955:Leucovorin; D005472:Fluorouracil; D008727:Methotrexate